Research and Markets: The Report Discovery Stage Partnering Agreements in Biopharma Contains Over 1000 Links to Online Cop

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4cc3a7/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Agreements in Biopharma" report to their offering.

The Discovery Stage Partnering Agreements in Biopharma report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement.

The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. This is the earliest stage of partnering undertaken by commercial entities with the objective of utilizing discovery technologies to identify promising drug candidates.

Key Benefits

Discovery Stage Partnering Agreements in Biopharma provides the reader with the following key benefits:

  • In-depth understanding of discovery stage partnering deal trends since 2000
  • Analysis of the structure of discovery stage partnering agreements with numerous real life case studies
  • Comprehensive access to over 1000 actual discovery stage partnering contracts entered into by the worlds biopharma companies*
  • Detailed access to actual discovery stage partnering contracts enter into by the leading fifty bigpharma companies*
  • Insight into the payment and deal terms included in a discovery stage partnering agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

*Subject to being published via regulatory requirements of the Securities Exchange Commission.

Report Scope: Discovery Stage Partnering Agreements in Biopharma is intended to provide the reader with an in-depth understanding of the discovery stage partnering trends and structure of deals entered into by leading biopharma companies worldwide.

Discovery Stage Partnering Agreements in Biopharma includes:

  • Trends in discovery stage partnering dealmaking in the biopharma industry since 2000
  • Analysis of discovery stage partnering deal structure
  • Average payment terms for discovery stage deals
  • Case studies of real-life discovery stage partnering deals
  • Access to over 1000 discovery stage partnering contract documents
  • The leading discovery stage partnering deals by value since 2000
  • Most active discovery stage partnering dealmakers since 2000
  • The leading discovery stage partnering resources

In Discovery Stage Partnering Agreements in Biopharma, the available contracts are listed by:

  • A-Z
  • Headline value
  • Therapeutic area
  • Deal type

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The Discovery Stage Partnering Agreements in Biopharma report provides comprehensive access to available contract documents for over 1000 discovery stage partnering deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Executive Summary:

Welcome to the Discovery Stage Partnering Agreements in Biopharma report.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement.

The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. This is the earliest stage of partnering undertaken by commercial entities with the objective of utilizing discovery technologies to identify promising drug candidates.

The report provides access to average discovery stage deal payment terms as announced between the parties. This data provides useful insight into the average and range of payments for upfront, milestone and royalty payments agreed for discovery stage deals.

This report complements our other development stage agreement in biopharma reports which cover Pre-clinical Stage Agreements and Clinical Stage Agreements in Biopharma.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains over 1000 links to online copies of actual clinical stage partnering contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company agreements allows assessment of the following:

  • What are the precise rights granted?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of discovery stage dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in discovery stage partnering as well as a discussion on the merits and attributes of dealmaking at the discovery stage of development.

Chapter 3 provides an overview of the structure of discovery stage partnering deal contracts. The chapter includes numerous case studies to enable understanding of discovery stage partnering deals.

Chapter 4 provides a review of the leading discovery stage partnering deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of discovery stage contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of all discovery stage agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by A-Z, therapeutic area, and deal type. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about discovery stage partnering, enabling thorough learning, education and due diligence prior and during the discovery stage dealmaking process.

Some of the Companies Mentioned include:

  • AstraZeneca
  • Barr Pharmaceuticals
  • Boehringer Ingelheim
  • Chugai
  • Daiichi Sankyo
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Mitsubishi
  • Mundipharma
  • Novartis AG
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Shire
  • Solvay
  • Stada
  • Takeda
  • Watson
  • Wyeth

For more information visit http://www.researchandmarkets.com/research/4cc3a7/discovery_stage_pa



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.